Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma
Clinical trial NCT07299331 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07299331
- Sponsor
- Zhengzhou University
- Status
- NOT_YET_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-01
- Primary completion
- 2031-04-30
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.